Heartflow Unveils 5,000-Patient NAVIGATE-PCI Registry, Shows $140M Savings and Fourfold MACE Risk
Heartflow presented long-term data from 15,000+ patients showing its Plaque Analysis predicts fourfold higher MACE risk and drives superior LDL<70 mg/dL achievement in nearly 3,800-patient DECIDE trial. It also launched its 5,000-patient NAVIGATE-PCI Registry and demonstrated AI-guided analysis yields $140M in payer savings within two years.
1. Robust MACE Prediction from Plaque Analysis
Heartflow’s Plaque Analysis tool evaluated over 15,000 patients with up to 16 years of follow-up, demonstrating that extensive coronary plaque volume predicts a fourfold increase in major adverse cardiovascular events, independent of traditional risk factors and stenosis severity.
2. DECIDE Registry Boosts LDL-Lowering Therapy Adoption
In the nearly 3,800-patient DECIDE Registry, centers using AI-driven Plaque Analysis saw significantly higher initiation of lipid-lowering therapy and increased proportion of patients reaching LDL targets below 70 mg/dL after one year, compared to stress-test-guided care.
3. Economic Sustainability Confirmed with $140M Savings
A US payer budget impact analysis showed that AI-guided coronary plaque analysis achieves cost parity with standard care within two years and delivers total population savings of $140 million, as the incremental cost to prevent a MACE event remains below treatment costs.
4. NAVIGATE-PCI Registry Launches for 5,000 Patients
Heartflow enrolled its first patient in the 5,000-patient NAVIGATE-PCI Registry to assess how AI-powered PCI Navigator influences clinical strategy, procedural efficiency and physician confidence by comparing CT-guided intervention planning to angiography alone.